Resource Library

Technology alone won't get you where you want to go. And that's why we won't ever just offer technology.

Filter by

Resource type

Application Note
Article
Brochure
Case Study
eBook
Flyer
Primary Literature
Scientific Brief
Scientific Poster/Poster Presentation
Webinar/Presentation

Application

Virus-like Particles
Cell Based Assays
Cell Line Development
Cell Therapy
CRISPR/Gene Editing
Protein Production
Stem Cells
Vaccines
Viral Vectors

Cell type

B Cells
Cancer Cell Lines
Cardiomyocytes
CHO
Dendritic Cells
Fibroblasts
HEK293
HSPCs
Insect Cell Lines (S2/Sf9/Sf21)
ion channels
iPSCs
Keratinocytes
MSCs
Neurons
NK Cells
NPCs/NSCs
Other Mammalian Cell Lines
PBMCs
T Cells

<style>

.alm-filter--text-wrap.has-button{ border: none;}

</style>

Scientific Brief

Cell Therapy

CRISPR/Gene Editing

SeQure™ Risk Assessment Services Align with FDA Guidance for Gene-Edited Human Gene Therapy Products

Our SeQure screening assays offer early insights into on- and off-target editing, addressing FDA and other regulatory expectations during guide design to reduce risk, streamline development and accelerate your path to the clinic.

Scientific Brief

Cell Therapy

CRISPR/Gene Editing

HSPCs

Base Editing of the Fetal Hemoglobin Promoter Yields Elevated Levels of HbF Expression in HSPC-Derived Red Blood Cells

This case study demonstrates the therapeutic potential of mutating a TT cluster at -123/124 in the HBG promoter in CD34+ HSPCs by targeted base editing. MaxCyte^® electroporation enabled the efficient delivery of gRNA and adenine base editor mRNA to primary human HSPCs.

Scientific Brief

CRISPR/Gene Editing

CAR NK

mRNA CAR NK Cells as Potential Anti-Sarcoma, Solid Tumor Therapy

The authors developed anti-EphA2 CAR NK cells and evaluated their ability to target in vitro and in vivo models of pediatric sarcoma.

Scientific Brief

Cell Based Assays

Cell Line Development

CHO

MaxCyte® Enabled Development of Landing-Pad CHO Cell Line for Mammalian Display

Mammalian display techniques have proven beneficial in the identification of antibodies for the lab and clinic. To simplify the screening of mammalian cells, MaxCyte electroporation helped develop a single-site landing-pad cell line, enabling targeted, single-copy sequence integration by RMCE.

TranspoCART cells that prolonged survival in a mouse disease model

Scientific Brief

Gene Therapy

TCR/CAR T

CAR T

T Cells

MaxCyte Enabled the Development and Rapid, Reproducible Manufacturing of TranspoCART Cells

Here, researchers developed a non-viral CAR T process using MaxCyte electroporation to deliver CAR transposon minicircle DNA and Sleeping Beauty 100X transposase mRNA (SB100X) to autologous patient T cells. The manufacturing process was reproducible across two different sites and generated TranspoCART cells that prolonged survival in a mouse disease model.

MaxCyte Electroporation Enables Efficient Antibody Discovery by Mammalian Display

Scientific Brief

Cell Based Assays

Protein Production

CHO

MaxCyte Electroporation Enables Efficient Antibody Discovery by Mammalian Display

In this pilot study, researchers transfected a subset of an IgG plasmid library to evaluate two electroporation methods in their mammalian display workflow. MaxCyte electroporation enabled better sequence diversity and library coverage with a streamlined workflow.

Scientific Brief

Virus-like Particles

CRISPR/Gene Editing

Cancer Cell Lines

HEK293

MaxCyte Electroporation Enables the Efficient, Scalable Packaging of CRISPR-Cas9 RNPs in Virus-Like Particles

Efficient, scalable cGMP-compliant transfection of up to 100 billion cells with MaxCyte’s Flow Electroporation technology could enable rapid clinical manufacturing of virus-like particles.

Scientific Brief

Cell Line Development

Protein Production

Vaccines

CHO

MaxCyte Enables Rapid Stable Cell Line Development for Enhanced HIV Vaccine Efficacy

Despite over thirty years of research, no approved HIV vaccine exists. The RV144 HIV vaccine trial demonstrated a modest 31% efficacy. MaxCyte electroporation efficiently transfected a custom CHO cell line, generating a high-yielding stable clone in under ten weeks to advance the development of rgp120 as an HIV vaccine candidate.

High-Yield Expression of Complex Proteins from Stable Pools Generated by MaxCyte® Electroporation

Scientific Brief

Antibody & Protein Production

Cell Line Development

Protein Production

CHO

High-Yield Expression of Complex Proteins from Stable Pools Generated by MaxCyte Electroporation

Cell line development is a well established process that remains an expensive bottleneck in the biotherapeutic pipeline. Here we present results demonstrating yields of complex biologics exceeding 8 g/L from extended-duration intensified batch culture of stable pools generated by MaxCyte electroporation of Genentech’s custom Bax/Bak DKO CHO cells.

Screenshot of pdf for Rapid Production of Assay-Ready Cells for GPCR Drug Discovery brief

Scientific Brief

Cell Based Assays

HEK293

Rapid Production of Assay Ready Cells for GPCR Drug Discovery

G-protein coupled receptors (GPCRs) regulate various physiological processes. They are targeted by hundreds of existing drugs used to treat or moderate conditions as diverse as asthma, hypertension, diabetes and Alzheimer’s disease. GPCRs have also been implicated in multiple forms of cancer, including colon, pancreatic and appendix cancer, increasing interest in GPCR drug discovery.

Pages: 123

Peer Reviewed Publications Featuring MaxCyte Electroporation

<span class="arrow-icon">View Publications</span>

Featured Science

<span class="arrow-icon">View Featured Science</span>

Resource Library

Filter by

Resource type

Application

Cell type

SeQure™ Risk Assessment Services Align with FDA Guidance for Gene-Edited Human Gene Therapy Products

Base Editing of the Fetal Hemoglobin Promoter Yields Elevated Levels of HbF Expression in HSPC-Derived Red Blood Cells

mRNA CAR NK Cells as Potential Anti-Sarcoma, Solid Tumor Therapy

MaxCyte® Enabled Development of Landing-Pad CHO Cell Line for Mammalian Display

MaxCyte Enabled the Development and Rapid, Reproducible Manufacturing of TranspoCART Cells

MaxCyte Electroporation Enables Efficient Antibody Discovery by Mammalian Display

MaxCyte Electroporation Enables the Efficient, Scalable Packaging of CRISPR-Cas9 RNPs in Virus-Like Particles

MaxCyte Enables Rapid Stable Cell Line Development for Enhanced HIV Vaccine Efficacy

High-Yield Expression of Complex Proteins from Stable Pools Generated by MaxCyte Electroporation

Rapid Production of Assay Ready Cells for GPCR Drug Discovery

Peer Reviewed Publications Featuring MaxCyte Electroporation

Featured Science

Receive upcoming events, new resources and more in your inbox

Cell Therapy

Gene Editing

Protein & Antibody Production

Cell Based Assays

Viral Vector

Vaccine Development

Industries

Cell & Gene Therapy

Discovery & Translational Research

Bioprocessing